Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0215

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910